

Product Portfolio: Novel Antibodies for Cancer Immunotherapy

Overview

Description	A newly established biotechnology company aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in metastatic solid tumors and rare hematological malignancies.
Key technology	The company focuses on T cells and Natural Killer (NK) cells, and is leveraging multiple advanced technologies, including human Ig transgenic (Tg) rodent derived fully human antibodies, NK cell engager bispecific antibodies, and multi-functional tri-specific antibodies.
Pipeline	A diversified pipeline unlocks the full power of immune cells to defeat cancers.
Indication	Hematologic malignances; solid tumors
Status	Therapeutic programs for single and/or combo therapy are expected to file patents starting 2021H1.

Collaboration Opportunity

Protheragen Inc. is actively seeking partners and investment for this company to advance the core products.

Key technology

State-of-Art Multi Specific Antibodies

- Bispecific NK cell engagers targeting a specific tumor antigen while leveraging the power of the innate immune system (NK Cells);
- Tri-specific antibodies blocks PD-L1 interactions with PD-1, internalizes sequestered inhibitory cytokines to unlock the inhibition of multiple immune cells, e.g. T cells, NK cells, dendritic cells (DCs) and macrophages, attracts and proliferate professional cytotoxic tumor killing T cells and NK cells.

E-mail: inquiry@protheragen.com


www.protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA

Pipeline

Diversified Pipeline

To overcome the limitations of traditional therapies, multiple approaches were developed to unlock the power of immune cells to fight cancer. A number of programs are ongoing, focusing on the treatment for hematological malignancies and solid tumors.



Indication

E-mail: inquiry@protheragen.com

www.protheragen.com

101-4 Colin Dr, Holbrook, NY 11741, USA

Hematologic Malignancies & Solid Tumors

The initial product portfolio focuses on both hematological malignancies such as cutaneous lymphoma (a rare subtype of non-Hodgkin lymphoma that starts in the skin) and solid tumors including triple negative breast cancer, ovarian, colon, kidney, renal and pancreatic cancers.

Hematologic Malignancies Hematologic malignancies most often begin in the bone marrow where blood is produced and when uncontrolled growth of abnormal blood cells overtakes the development of normal blood cells and interferes with the regular functions of these cells. Hematologic malignancies fall into three categories: leukemia, lymphoma, and myeloma. Non-Hodgkin lymphoma is the most common hematological malignancy, although it is nonetheless a rare disorder, accounting for less than 2% of all cancers. As the second most common hematological malignancy, there were an estimated 427,400 prevalent cases of multiple myeloma worldwide in 2013, according to the Global Burden of Disease (GBD) 2013 study.

Solid Tumors Solid tumors represent approximately 90% of human cancers. They can be either benign or malignant and develop in many parts of the human body, including breast, lung, prostate, colon, melanoma, bladder, and kidney. According to global cancer statistics in 2018, the most common cancer in the world is lung cancer and followed by female breast cancer. The third and fourth most common cancers are prostate and colorectal cancers, respectively.

Surgery, radiation, and chemotherapy are the traditional treatments for cancers. Immunotherapy is a rapidly growing field that aims to enhance the immune system's ability to eradicate tumors. One of the immunotherapies is immune effector cell retargeting for achieving anti-tumor activity.

Status

Present Status and Future Development

- Experienced Industrial Team in therapeutic antibody drug R&D.
- Proprietary Global Leading Antibody Discovery Technologies.
- Two state-of-art bispecific and tri-specific antibody technology platforms to unlock the full power of immune cells.

- Multiple Hematological & Solid Tumor Therapeutic Programs for single and/or combo therapy with checkpoint blockade, expected to file patents starting 2021H1.
- World Class Partnership with human Ig Tg rodent companies.